Digestive Diseases and Sciences

, Volume 45, Issue 9, pp 1792–1801 | Cite as

Effect of Bisphosphonates on Surface Hydrophobicity and Phosphatidylcholine Concentration of Rodent Gastric Mucosa

  • Lenard M. Lichtenberger
  • Jimmy J. Romero
  • George W. Gibson
  • Marion A. Blank

Abstract

Bisphosphonates are a family of chemically related zwitterionic molecules that are used clinically to retard bone resorption in individuals with osteoporosis and associated skeletal diseases. Inflammation and ulceration of the upper gastrointestinal tract by a mechanism that relates to a topical irritant action is associated with the consumption of some bisphosphonates. In the present study, we investigated the effects of three bisphosphonate molecules, pamidronate, alendronate, and risedronate on the surface hydrophobicity and phosphatidylcholine (PC) concentration of the antral mucosa. We also examined how these surface changes related to mucosal injury in an established rat model, in which the test compounds were administered in combination with indomethacin. We initially determined that a combination of pamidronate (300 mg/kg) and indomethacin (40 mg/kg) induced a significant reduction in mucosal surface hydrophobicity and macroscopic lesion formation by 15 min and mucosal PC concentration by 30 min, with the magnitude of these changes increasing over the 4-hr study period. An equivalent dose of alendronate or risedronate in combination with indomethacin produced modest or no macroscopic injury, respectively, to the antral mucosa over the 4-hr study, although the bisphosphonates clearly induced surface injury and some glandular necrosis when examined at the light microscopic level. These bisphosphonates also induced modest decreases in antral surface hydrophobicity and mucosal PC concentration that appeared to be related to their injurious potential. In conclusion, the variable toxicity of bisphosphonates to the antral mucosa appears to be associated with their ability to compromise the surface hydrophobic phospholipid barrier of the tissue, with pamidronate >>> alendronate > risedronate. This bisphosphonate effect on the surface barrier may trigger the development of mucosal injury and possible ulceration.

bisphosphonates hydrophobicity phospholipids ulcer stomach 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Fleisch H: Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62, 1997Google Scholar
  2. 2.
    Fleisch H: Bisphosphonates: pharmacology and use in treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 42:919-944, 1991Google Scholar
  3. 3.
    Maconi G, Bianchi Porro G: Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889-1890, 1995Google Scholar
  4. 4.
    Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322, 1994Google Scholar
  5. 5.
    De Groen PC, Lubbe DJ, Hirsch IJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996Google Scholar
  6. 6.
    Graham DY, Malaty HM, Goodgame R: Primary amino phosphonates: A new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am J Gastroenterol 92:1322-1325, 1997Google Scholar
  7. 7.
    Graham DY, Malaty HM: Alendronate gastric. Aliment Pharmacol Ther 13:515-519, 1999Google Scholar
  8. 8.
    Lanza FL: The effects of amino-versus alkyl-bisphosphonates on the healing of aspirin-induced stomach erosions. Am J Gastroenterol 91:1916, 1996Google Scholar
  9. 9.
    Peter CP, Kindt MV, Majka JA: Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009-1015, 1998Google Scholar
  10. 10.
    Blank MA, Ems BL, Gibson GW, Myers WR, Berman SK, Phipps RJ, Smith PN: Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 42:281-288, 1997Google Scholar
  11. 11.
    Elliott SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL: Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 62:77-91, 1998Google Scholar
  12. 12.
    Hills BA, Butler BD, Lichtenberger LM: The gastric mucosal barrier; the hydrophobic lining to the lumen of the stomach. Am J Physiol 244:G561-G568, 1983Google Scholar
  13. 13.
    Lichtenberger LM: The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 57:565-583, 1995Google Scholar
  14. 14.
    Goggin PM, Marrero JM, Spychal RI, Jackson PA, Corbishley CM, Northfield TC: Surface hydrophobicity of the gastric mucosa in Helicobacter infection: Effect of clearance and eradication. Gastroenterology 103:1486-1490, 1992Google Scholar
  15. 15.
    Asante M, Ahmed H, Patel P, Davis T, Finlayson C, Mendall M, Northfield; Gastric mucosal hydrophobicity in duodenal ulceration: role of Helicobacter pylori infection density and mucus lipids. Gastoenterology 113:449-454, 1997Google Scholar
  16. 16.
    Lichtenberger LM, Dial EJ, Ottlecz A, Romero JJ, Lechago J, Fox JG: Attenuation of hydrophobic phospholipid lining is an early event in Helicobacter felis-induced gastritis in mice. Dig Dis Sci 44:108-115, 1999Google Scholar
  17. 17.
    Goddard PJ, Hills BA, Lichtenberger LM: Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity? Am J Physiol 252:G421-G430, 1987Google Scholar
  18. 18.
    Lichtenberger LM, Wang Z-M, Romero JJ, Ulloa C, Perez JC, Giraud M-N, Barreto JC: Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids; insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1:154-158, 1995Google Scholar
  19. 19.
    Kao Y-C, Lichtenberger LM: Phospholipid-and neutral-lipid containing organelles of rat gastroduodenal mucous cells: Possible origin of the hydrophobic lining. Gastroenterology 101:7-21, 1991Google Scholar
  20. 20.
    Lichtenberger LM, Graziani LA, Dial EJ, Butler BD, Holls BA: Role of surface-active phospholipids in gastric cytoprotection. Science 219:1327-1329, 1983Google Scholar
  21. 21.
    Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM: Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94:1818-1822, 1999Google Scholar
  22. 22.
    Bligh EF, Dyer WJ: A rapid method of total lipid extraction and purification: Can J Biochem Physiol 37:911-917, 1959Google Scholar
  23. 23.
    Rouser G, Siratos AN, Fleisher S: Quantitative analysis of phospholipids by thin layer chromatography and phosphorous analysis of spots. Lipids 1:85-86, 1966Google Scholar
  24. 24.
    Skipski U, Peterson RF, Sanders J, Barclay M: Thin-layer chromatography of phospholipids using silica gel without calcium binder. J Lipid Res 4:227-228, 1963Google Scholar
  25. 25.
    Blank MA, Gibson G, Dierckman TA, Myers W, Phipps R, Smith P: Gastric damage with nitrogen-containing bisphosphonates (N-BPs) does not correlate with antiresorptive potency. Bone 22:46S, 1998Google Scholar
  26. 26.
    Lichtenberger LM, Romero JJ: Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus gel layer: implications on the role of ammonium in H. pylori induced gastritis. J Gastroenterol Hepatol 9:S13-S19, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Lenard M. Lichtenberger
    • 1
    • 2
  • Jimmy J. Romero
    • 1
    • 2
  • George W. Gibson
    • 1
    • 2
  • Marion A. Blank
    • 1
    • 2
  1. 1.Department of Integrative Biology & PharmacologyThe University of Texas Medical School at HoustonHouston
  2. 2.Procter & Gamble Pharmaceuticals Health Care Research CenterCincinnati

Personalised recommendations